Table I.
Treatment strategy.
| NLR, n (%) | PLR, n (%) | MLR, n (%) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Treatment | All groups (n=436) | NLR≤2.65 (n=346) | NLR>2.65 (n=90) | P-value | PLR ≤190.9 (n=382) | PLR >190.9 (n=54) | P-value | MLR ≤0.28 (n=275) | MLR>0.28 (n=159) | P-value |
| Chemotherapy | 0.0498 | 0.088 | 0.627 | |||||||
| No | 45 (10) | 41 (12) | 4 (4) | 43 (11) | 2 (4) | 30 (11) | 15 (9) | |||
| Yes | 391 (90) | 305 (88) | 86 (96) | 339 (89) | 52 (96) | 245 (89) | 144 (91) | |||
| Chemotherapy regimen | ||||||||||
| Total n for all chemotherapy patients | 391 | 305 | 86 | 339 | 52 | 245 | 144 | |||
| AC FAC | 302 (77) | 241 (79) | 61 (71) | 0.025 | 265 (78) | 37 (71) | 0.026 | 193 (79) | 108 (75) | 0.441 |
| AC + taxanes | 80 (20) | 56 (18) | 24 (28) | 66 (19) | 14 (27) | 47 (19) | 33 (23) | |||
| CMF | 8 (2) | 8 (3) | 0 | 8 (2) | 0 | 5 (2) | 2 (1) | |||
| Other | 1 (0) | 0 | 1 (1) | 0 | 1 (2) | 0 | 1 (1) | |||
| Local treatment | 0.042 | 0.0001 | 0.153 | |||||||
| Mastectomy | 278 (64) | 224 (65) | 54 (60) | 246 (64) | 32 (59) | 177 (64) | 99 (62) | |||
| Breast conservation surgery | 130 (30) | 105 (30) | 25 (28) | 119 (31) | 11 (20) | 85 (31) | 45 (28) | |||
| Without surgery | 28 (6) | 17 (5) | 11 (12) | 17 (4) | 11 (20) | 13 (5) | 15 (9) | |||
| Hormonotherapy | 0.015 | 0.006 | 0.012 | |||||||
| No | 149 (34) | 108 (31) | 41 (46) | 121 (32) | 28 (52) | 82 (30) | 67 (42) | |||
| Yes | 287 (66) | 238 (69) | 49 (54) | 261 (68) | 26 (48) | 193 (70) | 92 (58) | |||
| Radiotherapy | 0.981 | 0.359 | 0.225 | |||||||
| No | 111 (25) | 88 (25) | 23 (26) | 100 (26) | 11 (20) | 75 (27) | 35 (22) | |||
| Yes | 325 (75) | 258 (75) | 67 (74) | 282 (74) | 43 (80) | 200 (73) | 124 (78) | |||
Data are presented as n (%). AC, Adriamycin (or doxorubicin; 60 mg/m2) and Cyclophosphamide (600 mg/m2) treatment; FAC, Fluorouracil (500 mg/m2), Adriamycin (or doxorubicin; 50 mg/m2) and Cyclophosphamide (500 mg/m2) treatment; CMF, Cyclophosphamide (100 mg/m2), Methotrexate (40 mg/m2) and Fluorouracil (600 mg/m2) treatment.